Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The Cleveland ...
Credit: Shutterstock. The application is supported by data from the phase 3 Marigold study. The Food and Drug Administration (FDA) has accepted for Priority Review the New Drug Application for ...
Ztalmy is a neuroactive steroid GABAA receptor positive modulator designed to regulate brain activity by inhibiting the abnormal electrical discharges that cause seizures and status epilepticus. The ...
SHANGHAI, February 01, 2026--(BUSINESS WIRE)--Tenacia Biopharmaceuticals (Shanghai) Co., Ltd. ("Tenacia") and GOLDEN AGE HEALTH (SHANGHAI) CO., LTD., a subsidiary of ...
Please provide your email address to receive an email when new articles are posted on . Ganaxolone was generally well tolerated and significantly reduced the frequency of seizures associated with ...
Scientists at the Francis Crick Institute have found a new treatment target for CDKL5 deficiency disorder (CDD), one of the most common types of genetic epilepsy. CDD causes seizures and impaired ...
PHILADELPHIA— A devastating genetic disease called CDKL5 deficiency disorder (CDD), which strikes in early childhood, may be significantly treatable even in adulthood, a new study from the Perelman ...
LONDON--(BUSINESS WIRE)--The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today ...
LONDON--(BUSINESS WIRE)--The Loulou Foundation, a private foundation dedicated to the development of therapeutics for the neurodevelopmental condition CDKL5 Deficiency Disorder (CDD), announced today ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results